Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 billion. Investors are closely watching upcoming drug trial results later this year, which are crucial for supporting Novartis' premium valuation, reflected in its P/E ratio of 21.30. Financial health metrics like a Debt-to-Equity ratio of 1.22 and a Current Ratio of 0.85 provide insight into the company's stability ahead of the earnings release on July 21, 2026.
Novartis shares dropped over 12.5% after its Phase 3 HARBOR trial for del-desiran and Phase 3 HORIZON trial for pelacarsen both failed to meet primary endpoints. These failures mean the drugs did not show significant benefits over placebo for their t...
Novartis' failed cholesterol drug trial for pelacarsen caused a sharp 14% drop in its stock and dragged down the entire Lp(a) drug class, hitting Amgen hardest with a 10% decline despite Amgen's positive Phase 3 lung cancer trial results announced th...
Novartis shares fell up to 10% after its drug del-desiran failed to meet the primary endpoint in the Phase 3 HARBOR study for myotonic dystrophy type 1, showing no significant improvement over placebo. This setback follows another recent late-stage t...
Novartis shares fell sharply following the failure of its late-stage drug candidates pelacarsen and del-desiran in phase 3 trials, which impacts the company’s near-term growth prospects. Despite these setbacks, Novartis reaffirmed its revenue growth ...
